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Burkholderia pseudomalleia b s t r a c t
A new c-carbonic anhydrase (CA, EC 4.1.1.1) was cloned and characterized kinetically in the genome of
the bacterial pathogen Burkholderia pseudomallei, the etiological agent of melioidosis, an endemic disease
of tropical and sub-tropical regions of the world. The catalytic activity of this new enzyme, BpsCAc, is sig-
nificant with a kcat of 5.3  105 s1 and kcat/Km of 2.5  107 M1  s1 for the physiologic CO2 hydration
reaction. The inhibition constant value for this enzyme for 39 sulfonamide inhibitors was obtained.
Acetazolamide, benzolamide and metanilamide were the most effective (KIs of 149–653 nM) inhibitors
of BpsCAc activity, whereas other sulfonamides/sulfamates such as ethoxzolamide, topiramate, sulpiride,
indisulam, sulthiame and saccharin were active in the micromolar range (KIs of 1.27–9.56 lM). As
Burkholderia pseudomallei is resistant to many classical antibiotics, identifying compounds that interfere
with crucial enzymes in the B. pseudomallei life cycle may lead to antibiotics with novel mechanisms of
action.
 2016 Elsevier Ltd. All rights reserved.In all living organisms, the interconversion of CO2 and HCO3 is
balanced naturally to maintain the equilibrium between dissolved
inorganic carbon dioxide (CO2), carbonic acid (H2CO3), bicarbonate
(HCO3) and carbonate (CO32). All these molecules have a pivotal
function in all lifeforms. For example, CO2 is fixed as 3-phospho-
glycerate (3-PGA) in plants by the photosynthetic C3 cycle, through
the action of RuBisCo,1,2 which is the only enzyme capable of net
carbon assimilation in the chloroplast stroma; HCO3- is the sub-
strate of phosphoenolpyruvate carboxylase (PEPC), which is the
enzyme involved in the formation of oxaloacetate in the mesophyll
cells of the C4 photosynthetic plants3; moreover, HCO3- is the main
molecule used by other carboxylating enzymes involved in biosyn-thetic pathways of fatty acids, amino acids and nucleotides in ani-
mals. Thus, the HCO3/CO32 ratio is fundamental to buffering the
pH in many tissues and various organisms. For all organisms and
tissues, the spontaneous hydration/dehydration reaction (1) is very
slow at physiological pH.4
CO2 þH2OHCO3 þHþ ð1Þ
To face this problem, all life forms evolved a specific family of
metalloenzymes, the carbonic anhydrases (CAs, EC 4.2.1.1), with
the primary function to strongly accelerate the interconversion of
CO2 and HCO3.5–9 This superfamily includes seven distinct classes
known as the a-, b-, c-, d-, f-,g- and ɵ-CAs.10–18 These enzymes are
involved in many physiologic processes, such as photosynthesis,
respiration, CO2 transport, as well as metabolism of xenobiotics
(e.g., cyanate in Escherichia coli). Some of the catalytically active
a- and ɵ-CAs can also catalyze the hydrolysis of esters, such as
4-nitrophenyl acetate (4-NpA). However, no esterase activity was
detected so far for enzymes belonging to the other five classes
(b-, c-, d-, f-, and g-CAs).11–13,16,19–21
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classes. a- and c-CAs contain zinc ion (Zn2+) in their active site,
coordinated by three histidine residues and a water molecule/
hydroxide ion, whereas in b-CAs the zinc ion is coordinated by
two Cys and one His residues. In the search for antibiotics with a
novel mechanism of action, a large number of CAs have been inves-
tigated in detail in pathogenic bacteria such as Helicobacter pylori,
Brucella suis,Mycobacterium tuberculosis, Streptococcus pneumoniae,
Salmonella enterica, Vibrio cholerae, Legionella pneumophila, Porphy-
romonas gingivalis, Streptococcus mutans and others.9,16,17,22 It has
been shown that the use of inhibitors of this family of metalloen-
zymes leads to growth defects of the pathogen. Thus, it is feasible
that new strategies for the development of antiinfectives with a
new and less explored mechanism of action can be developed.
The classical CA inhibitors (CAIs) are the primary sulfonamides,
RSO2NH2, which have been in clinical use for more than 60 years
as diuretics, and systemically acting antiglaucoma drugs.23,24 For
example, there are several clinically used drugs (or agents in clin-
ical development) belonging to the sulfonamide or sulfamateSO2NH2
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Fig. 1. Sulfonamides/sulfamates thclasses, which show significant CAI inhibitory activity
(Fig. 1).1,25–32 However, recently sulfonamide/sulfamate CAIs have
emerged for targeting the bacterial proteins and have the potential
for use as antiinfectives.17,21,25,27,33–40 In Fig. 1, a large number of
sulfonamides/sulfamates are shown that are often used for the
screening of the inhibition profile of various CAs, including bacte-
rial enzymes belonging to all three classes (a, b and
c).6,8,9,11,13,14,41–44
Among the Gram-negative saprophytic bacteria living in water
and soil, Burkholderia pseudomallei is the etiological agent respon-
sible for melioidosis, which is an endemic disease of tropical and
sub-tropical regions.45 Humans can be infected by skin inoculation,
inhalation, and ingestion of contaminated water and soil. Infected
people can manifest symptoms, such as bacteremia with septic
shock, pneumonia, pericarditis, genitourinary infections, inflam-
mation of parotid glands, central nervous system infection, septic
arthritis, abscess involving spleen, liver and adrenal glands.45
We investigated the presence of CAs in the genome of B. pseudo-
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492 S. Del Prete et al. / Bioorganic & Medicinal Chemistry Letters 27 (2017) 490–495fundamentally resistant to penicillin, ampicillin, first-generation
and second-generation cephalosporins, macrolides, quinolones
and most aminoglycosides; ii) it has been reported that the optimal
proliferation temperature of this bacterium is around 40 C in neu-
tral or slightly acidic conditions (pH 6.8–7.0), which might be con-
trolled by CAs, which are enzymes that are involved in the pH
homeostasis in all living organisms.46
Owing to the limited therapeutic options for treating Burkholde-
ria pseudomallei induced infections and the pivotal role of CAs in
pH homeostasis, targeting the CA family is a promising to discover
new antibacterials devoid of resistance problems. B. pseudomallei
genome encodes for at least three b-CAs and one c-CA, but not
for a-class enzymes. Here, we report the inhibition profiles of
BpsCAc in comparison to those obtained for human CAs (a-CAs)
and other bacterial c-CAs using the sulfonamides/sulfamates that
are shown in Fig. 1. This study may be of interest for designing
new types of inhibitors that may have clinical applications.
In Table 1, the rate constants and related kinetic values (kcat, KM
and kcat/KM) for the c-CA identified in the genome of B. pseudoma-
llei, and the inhibition constant values (KI) for the inhibitor aceta-
zolamide (5-acetamido-1,3,4-thiadiazole-2-sulfonamide) and
BpsCAc are shown. These data were compared to the kinetic
parameters of other CAs belonging to a-, b- and c-classes identified
in different organisms. The catalytic activity of these enzymes was
determined using the ‘stopped-flow’ technique.47 The kinetic
parameters for BpsCAc were: kcat of 5.3  105 s1 and kcat/Km of2.5  107 M1  s1 (Table 1). BpsCAc possesses a moderate CO2
hydrase activity when compared with the human isoform hCA I,
which is similar to the bacterial c-CAs from various pathogenic
bacteria (Porphyromonas gingivalis, an oral cavity pathogenic bac-
terium; Vibrio cholerae, etiological agent of cholera;
Table 1).10,13,30,34,42,48–50 Furthermore, the BpsCAc activity was
effectively inhibited (KI of 149 nM) by the clinically used sulfon-
amide inhibitor acetazolamide.
To determine the hydratase activity of the BpsCAc, this enzyme
was analyzed using protonographic analysis,51–53 which is a new
technique in which pH changes resulting from CAs on SDS–PAGE
can be determined colorimetrically. In Fig. 2, protonograms
obtained using the commercially available bovine bCA (a-CA)
and the recombinant BpsCAc are shown.
The protonogram of bCA showed a single band of activity corre-
sponding to a monomer of 30 kDa corresponding to the mass of the
monomer bCA and consistent with mammalian a-CAs being active
as monomers (Fig. 2).21,22,44,54–56 The protonographic analysis of
BpsCAc showed a band of activity at the molecular weight
of 22 kDa. It has been reported that c-CAs catalyze the hydration
of carbon dioxide to bicarbonate and protons when the c-CAs
monomers assemble into a trimer to form a triangular motif with
a real molecular weight of about 65 kDa.57,58 The apparent molec-
ular weight of 22 kDa on the SDS-PAGE/protonogram is due to the
SDS concentration, which results from the separation of the tri-
meric state of the protein allowing the migration of the enzyme
Table 1
Comparison of the kinetic parameters for the CO2 hydration reaction catalyzed by BpsCAc, the human cytosolic isozymes hCA I and II (a-class CAs) and the c-CAs from Vibrio
cholerae (VchCAc) and P. gingivalis (PgiCAc). Acetazolamide inhibition data are also shown. Human isoenzymes were analyzed at 20 C and pH 7.5 in 10 mM HEPES buffer and
20 mM Na2SO4, while the bacterial enzymes were measured at 20 C, pH 8.3 in 20 mM TRIS buffer and 20 mM NaClO4.
Enzyme Activity level Class kcat (s1) kcat/Km (M1 s1) KI (acetazolamide) (nM)
hCA I Moderate a 2.0  105 5.0  107 250
hCA II Very high a 1.4  106 1.5  108 12
VchCAc Moderate c 7.39  105 6.4  107 473
PgiCAc Moderate c 4.1  105 5.4  107 324
BpsCAc Moderate c 5.3  105 2.5  107 149
Fig. 2. Protonographic analysis of BpsCAc. The gel was loaded with bCA and
BpsCAc. STD corresponds to standards and the yellow band denotes CA activity due
to the change of color of the pH indicator.
Table 2
Sulfonamides/sulfamates inhibition constants (KIs, nM) for the human a-CAs
(isoforms hCA I and II) and the c-CAs identified in the genome of V. cholera and B.
pseudomallei.
KIs, nM*
Inhibitor hCA I hCA II VchCAc BpsCAc
1 45,400 295 672 574
2 25,000 240 95.3 1720
3 28,000 300 93.6 1550
4 78,500 320 76.3 >50,000
5 25,000 170 80.6 >50,000
6 21,000 160 69.0 >50,000
7 8300 60 73.6 >50,000
8 9800 110 73.6 12,500
9 6500 40 95.3 >50,000
10 6000 70 544 >50,000
11 5800 63 87.1 14,000
12 8400 75 563 23,500
13 8600 60 66.2 18,400
14 9300 19 69.9 1810
15 6 2 88.5 9650
16 164 46 556 10,800
17 185 50 6223 1825
18 109 33 5100 1500
19 95 30 4153 1838
20 690 12 5570 1810
21 55 80 764 1335
22 21,000 125 902 1805
23 23,000 133 273 1700
24 24,000 125 73.3 24,500
AAZ 250 12 473 149
MZA 50 14 494 1595
EZA 25 8 85.1 1865
DCP 1200 38 1230 >50,000
DZA 50,000 9 87.3 2260
BRZ 45,000 3 93.0 1270
BZA 15 9 77.6 653
TPM 250 10 68.8 3010
ZNS 56 35 725 >50,000
SLP 1200 40 77.9 5600
IND 31 15 91.3 1800
VLX >50,000 43 817 >50,000
CLX 50,000 21 834 >50,000
SLT 374 9 464 8900
SAC 18,540 5959 550 1550
HCT 328 290 500 >50,000
* Mean from 3 different assays. Errors in the range of ±10% of the reported values
(data not shown).
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dence of the inactive monomeric form of BpsCAc is expected
because at the end of the electrophoretic run, the SDS is removed
from the gel. This procedure led to the rearrangement of c-CA
monomers in the gel and the final result is the reconstitution of
the active trimeric form of the c-CA.52,53
Here, we report the sulfonamide/sulfamate inhibition study of
BpsCAc comparing it with data obtained for the human cytosolic
isozymes hCA I and II (a-class CAs) and the c-CAs from Vibrio
cholerae (VchCAc). The following structure-activity relationship
(SAR) may be concluded by considering the inhibition data in
Table 2:
(i) BpsCAc is less sensitive to sulfonamide CAIs compared to
other a- (e.g., hCA II) or c-CAs (e.g., VchCAc) investigated
earlier,8 for which many nanomolar (and low nanomolar)
inhibitors were found (Table 2). It may be observed that only
three sulfonamides had KIs in the range of 149–653 nM, all
the other ones having inhibition constants >1 lM. The most
effective BpsCAc inhibitors were acetazolamide AAZ, benzo-
lamide BZA, and metanilamide 1. They incorporate both aro-
matic (1) and heterocyclic (AAZ, BZA) sulfonamide motifs.
However, as discussed below, small changes in their scaf-
folds can result in a dramatic decrease in inhibitory activity.
(ii) Moderate to low BpsCAc inhibitory activity was observed for
the following derivatives: 2, 3, 14, 15, 17–23, MZA, EZA,
TPM, SLP, IND, SLT and SAC, which had KIs in the range of
1270–9560 nM (Table 2). Apart from the clinically used
derivatives, which incorporate heterocyclic rings (MZA,
EZA), aromatic (SLP, IND, SLT) and sugar (TPM) scaffolds,
the secondary, acyl-sulfonamide SAC was also among thistype of CAIs. Other derivatives in this category are either
simple aromatic compounds (sulfanilamide 2, benzene-1,3-
disulfonamide 3, 4-hydroxybenzenesulfonamide 15, its
hydroxyethyl congener 17, 4-carboxybenzenesulfonamide
18) or incorporate more elaborated scaffolds (as in 19–23)
that are prevalent for the sulfonylated sulfonamide type
(e.g., aminobenzolamide 20 and benzolamide BZA are typi-
cal examples of such a scaffold). However, relatively minor
changes in the scaffold results in a dramatic change in the
CA inhibitory activity. For example, the isomers 1 and 2 that
differ in the position of the amino group with respect to the
494 S. Del Prete et al. / Bioorganic & Medicinal Chemistry Letters 27 (2017) 490–495sulfonamide, differ in a factor of 3 in their BpsCAc inhibitory
activity. In the structurally related series 15–17, the com-
pound incorporating the longer spacer (n = 2, 17) inhibited
BpsCAc more effectively by over a factor of 5 than the com-
pound 15 that had a shorter spacer (n = 0). However, the
derivative with the hydroxymethyl moiety 16 was a much
weaker inhibitor, with a KI of 10.8 lM. Other such examples
are abundant in this series of compounds that was investi-
gated, with the deprotected acetazolamide 13 being less
effective as an inhibitor than AAZ by over a factor of 100.
In contrast, for methazolamide and the deacetylated metha-
zolamide (14) pair, the difference of activity is minor, with
14 being only 1.13 times weaker as an inhibitor compared
toMZA (Table 2). All these data are indicative of the fact that
the recognition between the enzyme active site and the inhi-
bitor molecules is governed bymultiple factors that are chal-
lenging to elucidate without an X-ray crystal structure of the
enzyme or high-resolution hydrogen deuterium exchange
data. In fact, up until now, a very limited number of c-CAs
have been crystallized, and no crystal structures have been
reported for a c-CA and inhibitor complex.57–60
(iii) The inhibitory action against BpsCAc was very low for the
following compounds: 8, 11–13, 16 and 24, which had KIs
in the range of 10,800–24,500 nM. Again, they belong to
heterogeneous classes of sulfonamides, with aromatic
monosulfonamides (8, 16, 24), disulfonamides (11, 12), and
a heterocylic sulfonamide derivative, deacetylated acetazo-
lamide 13 (Table 1).
(iv) A number of the investigated sulfonamides did not inhibit
BpsCAc up to 50 lM, which is the maximum concentration
of inhibitor in the assay system. They are: 4–7, 9, 10, DCP,
ZNS, VLX, CLX and HCT. Whereas some of these compounds
have rather bulky, complicated scaffold (VLX, CLX and HCT),
which could be sterically hindered from binding within the
rather shallow c-CA active site, the simple derivatives 4–7,
9 and 10 should not experience such issues with binding.
It is thus obvious that SAR for the inhibition of this enzyme
is rather complex and poorly understood with the available
data at this moment.
(v) The inhibition profile of BpsCAc is very different from that of
other a- or c-CAs of mammalian or bacterial origin, making
this enzyme a peculiar case, which deserves further
investigation.
In conclusion, we have cloned and characterized the kinetic pro-
file of a newc-CA in the genomeof thebacterial pathogenBurkholde-
ria pseudomallei, the etiological agent of melioidosis, an endemic
disease of tropical and sub-tropical regions of the world. For the
physiologic CO2 hydration reaction, this new enzyme, BpsCAc, exhi-
bits significant catalytic activity (kcat of 5.3  105 s1 and kcat/Km of
2.5  107 M1  s1). Fewsulfonamideswere effectiveBpsCAc inhi-
bitors, with acetazolamide, benzolamide and metanilamide being
themost effective inhibitors identified (KIs of 149–653 nM)whereas
other sulfonamides/sulfamates such as ethoxzolamide, topiramate,
sulpiride, indisulam, sulthiameandsaccharinwere less effective (KIs
of 1.27–9.56 lM). As Burkholderia pseudomallei is resistant to many
classical antibiotics, discovering compounds that interferewith cru-
cial enzymes in its life cycle may lead to the development of antibi-
otics with novel mechanisms of action.
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